BL Pharmtech Corp. (KOSDAQ:065170)
South Korea · Delayed Price · Currency is KRW 1,823.00
-242.00 (-11.72%)
At close: May 29, 2026
BL Pharmtech Income Statement
Financials in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Fiscal Year | TTM | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Mar '26 Mar 31, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Operating Revenue | 5,036 | 6,506 | 8,806 | 24,525 | 22,523 | 84,440 |
Other Revenue | -0 | -0 | -0 | - | - | -0 |
| 5,036 | 6,506 | 8,806 | 24,525 | 22,523 | 84,440 | |
Revenue Growth (YoY) | -39.57% | -26.12% | -64.10% | 8.89% | -73.33% | 28.54% |
Cost of Revenue | 2,132 | 2,814 | 2,885 | 10,964 | 9,801 | 63,367 |
Gross Profit | 2,903 | 3,692 | 5,921 | 13,561 | 12,722 | 21,073 |
Selling, General & Admin | 4,589 | 5,961 | 8,287 | 19,473 | 16,825 | 24,014 |
Amortization of Goodwill & Intangibles | 85.21 | 148.75 | 341.79 | 338.08 | - | - |
Operating Expenses | 3,344 | 5,724 | 10,265 | 20,680 | 17,510 | 24,668 |
Operating Income | -440.35 | -2,032 | -4,345 | -7,119 | -4,789 | -3,595 |
Interest Expense | -775.68 | -899.73 | -829.33 | -1,573 | -2,206 | -2,591 |
Interest & Investment Income | 272.16 | 259.12 | 302.46 | 51.42 | 131.12 | 103 |
Earnings From Equity Investments | -10,651 | -10,651 | -1,668 | -469.42 | -358.97 | -51.29 |
Currency Exchange Gain (Loss) | -21.68 | -31.07 | 24.38 | 9.56 | 64.6 | -374.37 |
Other Non Operating Income (Expenses) | -167.06 | -27.96 | 1,638 | -2,854 | -2,079 | -1,012 |
EBT Excluding Unusual Items | -11,783 | -13,383 | -4,877 | -11,955 | -9,237 | -7,521 |
Gain (Loss) on Sale of Investments | -3,262 | -3,262 | -17.56 | - | 283.8 | 67.12 |
Gain (Loss) on Sale of Assets | 3.78 | 2.34 | 78.66 | 53.01 | - | 3,084 |
Asset Writedown | - | - | -950 | -2,900 | -5,151 | -16,238 |
Other Unusual Items | -138.28 | -138.28 | - | 944.78 | 31.04 | 38.48 |
Pretax Income | -15,180 | -16,781 | -5,766 | -13,856 | -14,073 | -20,570 |
Income Tax Expense | 18.28 | 5.94 | -49.36 | -46.23 | 363.26 | -462.69 |
Earnings From Continuing Operations | -15,199 | -16,787 | -5,717 | -13,810 | -14,437 | -20,107 |
Earnings From Discontinued Operations | - | - | - | 13,952 | 787.1 | - |
Net Income to Company | -15,199 | -16,787 | -5,717 | 141.63 | -13,649 | -20,107 |
Minority Interest in Earnings | 9.35 | 9.63 | 10.4 | -290.47 | -253.65 | -104.49 |
Net Income | -15,189 | -16,778 | -5,706 | -148.85 | -13,903 | -20,211 |
Net Income to Common | -15,189 | -16,778 | -5,706 | -148.85 | -13,903 | -20,211 |
Shares Outstanding (Basic) | 27 | 27 | 27 | 27 | 27 | 26 |
Shares Outstanding (Diluted) | 27 | 27 | 27 | 27 | 27 | 26 |
Shares Change (YoY) | 0.01% | 0.05% | -0.09% | - | 1.33% | 18.44% |
EPS (Basic) | -570.19 | -628.85 | -214.00 | -5.58 | -520.90 | -767.32 |
EPS (Diluted) | -570.19 | -628.85 | -214.00 | -5.58 | -520.90 | -767.32 |
Free Cash Flow | -2,480 | -283.76 | -4,203 | 7,680 | -12,706 | 2,510 |
Free Cash Flow Per Share | -93.11 | -10.64 | -157.64 | 287.73 | -476.04 | 95.28 |
Gross Margin | 57.66% | 56.74% | 67.24% | 55.30% | 56.48% | 24.96% |
Operating Margin | -8.74% | -31.24% | -49.34% | -29.03% | -21.26% | -4.26% |
Profit Margin | -301.63% | -257.89% | -64.81% | -0.61% | -61.73% | -23.94% |
Free Cash Flow Margin | -49.25% | -4.36% | -47.74% | 31.31% | -56.41% | 2.97% |
EBITDA | 46.09 | -1,476 | -3,492 | -6,271 | -3,888 | -146.75 |
EBITDA Margin | 0.92% | -22.69% | -39.66% | -25.57% | -17.26% | -0.17% |
D&A For EBITDA | 486.44 | 556.32 | 852.35 | 848.1 | 900.55 | 3,448 |
EBIT | -440.35 | -2,032 | -4,345 | -7,119 | -4,789 | -3,595 |
EBIT Margin | -8.74% | -31.24% | -49.34% | -29.03% | -21.26% | -4.26% |
Advertising Expenses | - | 766.18 | 1,643 | 3,675 | 2,206 | 2,535 |